Remaining concerns were expressed for a potential link between pioglitazone (117) and a novel class of oral glucose-lowing drug Sodium-glucose cotransporter 2 (SGLT2) inhibitors (118) with bladder cancer. This evidence concerns the gene SLC5A2 and urinary bladder cancer.